Turning Point Brands Announces Third Quarter 2021 Results; Updates 2021 Guidance and Increases Share Repurchase Authorization
Turning Point Brands, Inc. (TPB) reported Q3 2021 net sales of $109.9 million, up 5.5% year-over-year, and a net income increase of 49.3% to $13.4 million. Adjusted EBITDA also rose by 9.9% to $26.3 million. Zig-Zag Products saw significant growth with a 17.4% sales increase, while Stoker's Products and NewGen Products faced mixed results. The company announced a $30.7 million increase in its share repurchase authorization to boost shareholder value. Challenges remain due to regulatory factors impacting the vape segment. Full-year net sales guidance was revised to $433-$443 million.
- Net sales increased 5.5% year-over-year to $109.9 million.
- Net income increased by 49.3% to $13.4 million.
- Adjusted EBITDA rose by 9.9% to $26.3 million.
- Zig-Zag Products segment grew 17.4%, driving overall sales.
- Share repurchase authorization increased by $30.7 million to $50 million.
- NewGen Products sales decreased by 3.2%, impacted by regulatory challenges.
- Revised full-year net sales guidance down from $447-$462 million to $433-$443 million.
-Q3 2021 Net Sales Increased 5.5 Percent Year-Over-Year
-Q3 2021 Adjusted EBITDA Increased 9.9 Percent Year-Over-Year
Q3 2021 vs. Q3 2020
-
Net sales increased 5.5 percent to
$109.9 million -
Gross profit increased 12.3 percent to
$54.3 million -
Net income increased 49.3 percent to
$13.4 million -
Adjusted EBITDA increased 9.9 percent to
(see Schedule A for a reconciliation to net income)$26.3 million -
Diluted EPS of
and Adjusted Diluted EPS of$0.65 as compared to$0.72 and$0.44 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)$0.69
“Our third quarter performance fell within our expectations with sales growth of
Zig-Zag Products Segment (38 percent of total net sales in the quarter)
For the third quarter, net sales of Zig-Zag Products increased 17.4 percent to
For the quarter, Zig-Zag Products segment gross profit increased 11.5 percent to
“Our growth initiatives within Zig-Zag continue to deliver strong results for the segment,” added
Stoker’s Products Segment (28 percent of total net sales in the quarter)
For the third quarter, net sales of Stoker’s Products increased 2.4 percent to
For the quarter, the Stoker’s Products segment gross profit increased 6.6 percent to
“Our Stoker’s MST business continued its strong growth trajectory and market share gains,” said Purdy. “Our loose-leaf chew business faced a tough prior year comparison but was in-line with the comparable 2019 period.”
NewGen Products Segment (34 percent of total net sales in the quarter)
For the third quarter, net sales of NewGen Products decreased 3.2 percent to
NewGen Products gross profit increased 22.4 percent to
“NewGen continues to manage through a rapidly evolving market driven by the uncertainty around the PMTA regulatory environment,” said Purdy. “We are encouraged that our proprietary products are under review by the FDA and look forward to engaging with the agency as it reviews our applications.”
Recent Events
Share Repurchase Authorization Increase
On
The repurchase authorization permits shares to be repurchased in open market or private transactions, through block trades, and pursuant to any trading plan or other arrangements. The timing, manner, price and amount of any repurchases will be determined by the Company’s management in its discretion and will be subject to economic and market conditions, stock price, applicable legal requirements and other factors. The repurchase authorization does not obligate the Company to purchase any specific number of shares and may be suspended or discontinued at any time.
FDA Rescinds Previous Market Denial Order for TPB’s Vapor Products
On
Increased Equity Stake in ReCreation Marketing
On
Performance Measures in the Third Quarter
Third quarter consolidated selling, general and administrative (“SG&A”) expenses were
The third quarter SG&A included the following notable items:
-
of stock options, restricted stock and incentive expense as compared to$1.8 million in the year-ago period$0.8 million -
of FDA PMTA-related expenses compared to$1.0 million in the year-ago period$5.3 million -
in outbound freight expense compared to$4.9 million in the year-ago period with the increase due to higher shipping costs on vapor products related to PACT Act implementation and higher freight costs across all segments$3.8 million
Total gross debt as of
During the quarter, the Company spent
2021 Outlook
Primarily as a result of evolving market dynamics driven by the FDA regulatory environment along with further implementation of the PACT Act, and to a lesser extent supply chain-related delays pushing some sales of new products into the first quarter of 2022, the Company is revising its annual guidance provided on
-
Net sales of
to$433 (compared to previous guidance of$443 million to$447 ), which assumes:$462 million - Strong double-digit sales growth for Zig-Zag Products
- Mid-to-high single-digit sales growth for Stoker’s Products (compared to previous guidance of high-single-digit sales growth)
- A decline in sales for NewGen Products (compared to previous guidance of flat sales growth) which includes a double-digit decline in our vape distribution business (compared to previous guidance of low single-digit decline) offset by expected growth in Nu-X
-
Adjusted EBITDA of
to$104 (compared to previous guidance of$108 million to$108 )$113 million
Other projections for 2021 include:
-
Stock compensation and non-cash incentive expense of
$8 million -
Cash interest expense of
and GAAP interest expense of$19 million $21 million - Effective income tax rate of 23 percent to 24 percent
-
Capital expenditures of
$6 million
For the fourth quarter of 2021, TPB projects:
-
Net sales of
to$93 with growth in the Zig-Zag and Stoker’s segments and a double-digit decline in NewGen$103 million
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the
Financial Statements Follow:
Consolidated Statement of Income | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
Three Months Ended |
|||||||
2021 |
2020 |
||||||
Net sales | $ |
109,904 |
|
$ |
104,174 |
|
|
Cost of sales |
|
55,635 |
|
|
55,867 |
|
|
Gross profit |
|
54,269 |
|
|
48,307 |
|
|
Selling, general, and administrative expenses |
|
31,894 |
|
|
32,286 |
|
|
Operating income |
|
22,375 |
|
|
16,021 |
|
|
Interest expense, net |
|
5,397 |
|
|
3,539 |
|
|
Investment income |
|
(157 |
) |
|
(3 |
) |
|
Gain on extinguishment of debt |
|
(375 |
) |
|
- |
|
|
Net periodic income, excluding service cost |
|
- |
|
|
1,188 |
|
|
Income before income taxes |
|
17,510 |
|
|
11,297 |
|
|
Income tax expense |
|
4,073 |
|
|
2,277 |
|
|
Consolidated net income |
|
13,437 |
|
|
9,020 |
|
|
Net loss attributable to non-controlling interest |
|
(31 |
) |
|
- |
|
|
Net income attributable to |
$ |
13,468 |
|
$ |
9,020 |
|
|
Basic income per common share: | |||||||
Net income attributable to |
$ |
0.71 |
|
$ |
0.47 |
|
|
Diluted income per common share: | |||||||
Net income attributable to |
$ |
0.65 |
|
$ |
0.44 |
|
|
Weighted average common shares outstanding: | |||||||
Basic |
|
18,897,974 |
|
|
19,240,187 |
|
|
Diluted |
|
22,364,807 |
|
|
22,839,797 |
|
|
Supplemental disclosures of statement of income information: | |||||||
Excise tax expense | $ |
6,040 |
|
$ |
5,810 |
|
|
FDA fees | $ |
163 |
|
$ |
135 |
|
|
Consolidated Balance Sheet | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
ASSETS | 2021 |
2020 |
|||||
Current assets: | |||||||
Cash | $ |
130,551 |
|
$ |
41,765 |
|
|
Accounts receivable, net of allowances of |
|
8,507 |
|
|
9,331 |
|
|
Inventories |
|
98,605 |
|
|
85,856 |
|
|
Other current assets |
|
27,113 |
|
|
26,451 |
|
|
Total current assets |
|
264,776 |
|
|
163,403 |
|
|
Property, plant, and equipment, net |
|
17,596 |
|
|
15,524 |
|
|
Deferred income taxes |
|
- |
|
|
610 |
|
|
Right of use assets |
|
15,984 |
|
|
17,918 |
|
|
Deferred financing costs, net |
|
415 |
|
|
641 |
|
|
|
162,415 |
|
|
159,621 |
|
||
Other intangible assets, net |
|
87,962 |
|
|
79,422 |
|
|
Master Settlement Agreement (MSA) escrow deposits |
|
31,763 |
|
|
32,074 |
|
|
Other assets |
|
42,810 |
|
|
26,836 |
|
|
Total assets | $ |
623,721 |
|
$ |
496,049 |
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ |
13,151 |
|
$ |
9,201 |
|
|
Accrued liabilities |
|
33,349 |
|
|
35,225 |
|
|
Current portion of long-term debt |
|
7,485 |
|
|
12,000 |
|
|
Other current liabilities |
|
71 |
|
|
203 |
|
|
Total current liabilities |
|
54,056 |
|
|
56,629 |
|
|
Notes payable and long-term debt |
|
413,553 |
|
|
302,112 |
|
|
Deferred income taxes |
|
1,654 |
|
|
- |
|
|
Lease liabilities |
|
14,201 |
|
|
16,117 |
|
|
Other long-term liabilities |
|
- |
|
|
3,704 |
|
|
Total liabilities |
|
483,464 |
|
|
378,562 |
|
|
Commitments and contingencies | |||||||
Stockholders' equity: | |||||||
Preferred stock; |
|
- |
|
|
- |
|
|
Common stock, voting, |
|
197 |
|
|
195 |
|
|
Common stock, nonvoting, |
|
- |
|
|
- |
|
|
Additional paid-in capital |
|
107,269 |
|
|
102,423 |
|
|
Cost of repurchased common stock | |||||||
(817,701 shares at |
|
(30,672 |
) |
|
(10,191 |
) |
|
Accumulated other comprehensive income loss |
|
(123 |
) |
|
(2,635 |
) |
|
Accumulated earnings |
|
61,052 |
|
|
23,645 |
|
|
Non-controlling interest |
|
2,534 |
|
|
4,050 |
|
|
Total stockholders' equity |
|
140,257 |
|
|
117,487 |
|
|
Total liabilities and stockholders' equity | $ |
623,721 |
|
$ |
496,049 |
|
|
Consolidated Statement of Cash Flows | |||||||
(dollars in thousands) | |||||||
(unaudited) | |||||||
Nine Months Ended |
|||||||
2021 |
2020 |
||||||
Cash flows from operating activities: | |||||||
Consolidated net income | $ |
40,007 |
|
$ |
23,814 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Loss on extinguishment of debt |
|
5,331 |
|
|
- |
|
|
Pension settlement and curtailment loss |
|
- |
|
|
1,188 |
|
|
Impairment loss |
|
- |
|
|
149 |
|
|
(Gain) loss on sale of property, plant, and equipment |
|
(2 |
) |
|
36 |
|
|
Depreciation expense |
|
2,313 |
|
|
2,482 |
|
|
Amortization of other intangible assets |
|
1,431 |
|
|
1,304 |
|
|
Amortization of deferred financing costs |
|
1,895 |
|
|
1,670 |
|
|
Deferred income taxes |
|
1,528 |
|
|
2,259 |
|
|
Stock compensation expense |
|
6,015 |
|
|
1,986 |
|
|
Noncash lease (income) expense |
|
(49 |
) |
|
179 |
|
|
Gain on MSA escrow deposits |
|
(144 |
) |
|
- |
|
|
Changes in operating assets and liabilities: | |||||||
Accounts receivable |
|
1,324 |
|
|
(1,877 |
) |
|
Inventories |
|
(10,970 |
) |
|
(2,208 |
) |
|
Other current assets |
|
(491 |
) |
|
(829 |
) |
|
Other assets |
|
685 |
|
|
1,941 |
|
|
Accounts payable |
|
3,488 |
|
|
(3,200 |
) |
|
Accrued postretirement liabilities |
|
- |
|
|
(54 |
) |
|
Accrued liabilities and other |
|
(2,796 |
) |
|
4,359 |
|
|
Net cash provided by operating activities | $ |
49,565 |
|
$ |
33,199 |
|
|
Cash flows from investing activities: | |||||||
Capital expenditures | $ |
(4,391 |
) |
$ |
(3,420 |
) |
|
Acquisitions, net of cash acquired |
|
(16,416 |
) |
|
(37,735 |
) |
|
Payments for investments |
|
(16,657 |
) |
|
- |
|
|
Restricted cash, MSA escrow deposits |
|
(14,783 |
) |
|
- |
|
|
Proceeds on the sale of property, plant and equipment |
|
2 |
|
|
3 |
|
|
Net cash used in investing activities | $ |
(52,245 |
) |
$ |
(41,152 |
) |
|
Cash flows from financing activities: | |||||||
Proceeds from Senior Secured Notes | $ |
250,000 |
|
$ |
- |
|
|
Payments of 2018 first lien term loan |
|
(130,000 |
) |
|
(8,000 |
) |
|
Settlement of interest rate swaps |
|
(3,573 |
) |
|
- |
|
|
Payment of promissory note |
|
(9,625 |
) |
|
- |
|
|
Payment of IVG note |
|
- |
|
|
(4,240 |
) |
|
Proceeds from unsecured notes |
|
- |
|
|
7,485 |
|
|
|
- |
|
|
(1,737 |
) |
||
Payment of dividends |
|
(3,056 |
) |
|
(2,846 |
) |
|
Payments of financing costs |
|
(6,921 |
) |
|
(194 |
) |
|
Exercise of options |
|
2,071 |
|
|
303 |
|
|
Redemption of options |
|
(2,111 |
) |
|
- |
|
|
Common stock repurchased |
|
(20,481 |
) |
|
(7,665 |
) |
|
Net cash provided by (used in) financing activities | $ |
76,304 |
|
$ |
(16,894 |
) |
|
Net increase (decrease) in cash | $ |
73,624 |
|
$ |
(24,847 |
) |
|
Effect of foreign currency translation on cash | $ |
235 |
|
$ |
- |
|
|
Cash, beginning of period: | |||||||
Unrestricted |
|
41,765 |
|
|
95,250 |
|
|
Restricted |
|
35,074 |
|
|
32,074 |
|
|
Total cash at beginning of period |
|
76,839 |
|
|
127,324 |
|
|
Cash, end of period: | |||||||
Unrestricted |
|
130,551 |
|
|
67,403 |
|
|
Restricted |
|
20,147 |
|
|
35,074 |
|
|
Total cash at end of period | $ |
150,698 |
|
$ |
102,477 |
|
|
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in
We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation and amortization. We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income” as operating income excluding depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-
In accordance with
Schedule A | ||||||
Reconciliation of GAAP Net Income to Adjusted EBITDA | ||||||
(dollars in thousands) | ||||||
(unaudited) | ||||||
Three Months Ended |
||||||
|
||||||
2021 |
2020 |
|||||
Net income attributable to |
$ |
13,468 |
|
$ |
9,020 |
|
Add: | ||||||
Interest expense, net |
|
5,397 |
|
|
3,539 |
|
Gain on extinguishment of debt |
|
(375 |
) |
|
- |
|
Income tax expense |
|
4,073 |
|
|
2,277 |
|
Depreciation expense |
|
767 |
|
|
809 |
|
Amortization expense |
|
477 |
|
|
477 |
|
EBITDA | $ |
23,807 |
|
$ |
16,122 |
|
Components of Adjusted EBITDA | ||||||
Other (a) |
|
- |
|
|
1,188 |
|
Stock options, restricted stock, and incentives expense (b) |
|
1,752 |
|
|
772 |
|
Transactional expenses (c) |
|
(232 |
) |
|
570 |
|
FDA PMTA (d) |
|
960 |
|
|
5,271 |
|
Adjusted EBITDA | $ |
26,287 |
|
$ |
23,923 |
|
(a) |
Represents non-cash pension expense (income) and foreign exchange hedging. |
|
(b) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. |
|
(c) |
Represents the fees incurred for transaction expenses. |
|
(d) |
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). |
Schedule B | |||||||
Reconciliation of GAAP diluted EPS to Adjusted diluted EPS | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | Three Months Ended | ||||||
2021 |
2020 |
||||||
GAAP EPS | $ |
0.65 |
|
$ |
0.44 |
|
|
Other (a) |
|
- |
|
|
0.04 |
|
|
Gain on extinguishment of debt (b) |
|
(0.01 |
) |
|
- |
|
|
Stock options, restricted stock, and incentives expense (c) |
|
0.06 |
|
|
0.03 |
|
|
Transactional expenses (d) |
|
(0.01 |
) |
|
0.02 |
|
|
FDA PMTA (e) |
|
0.03 |
|
|
0.18 |
|
|
Tax (expense) benefit (f) |
|
0.00 |
|
|
(0.02 |
) |
|
Adjusted diluted EPS (g) | $ |
0.72 |
|
$ |
0.69 |
|
|
Totals may not foot due to rounding |
(a) |
Represents non-cash pension expense (income) and foreign exchange hedging reporting tax effected at the quarterly tax rate. |
|||
(b) |
Represents gain on extinguishment of debt tax effected at the quarterly tax rate. |
|||
(c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate. |
|||
(d) |
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate. |
|||
(e) |
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate. |
|||
(f) |
Represents adjustment from quarterly tax rate to annual projected tax rate of |
|||
(g) |
Diluted shares outstanding includes the full 3.2 million share dilution of debt conversion without a 1.1 million share offsetting impact from capped call transactions |
Schedule C | ||||||||||||||||||||||||
Reconciliation of GAAP Operating Income to Adjusted Operating Income | ||||||||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||
Consolidated | Zig-Zag Products | Stoker's Products | NewGen Products | |||||||||||||||||||||
3rd Quarter | 3rd Quarter | 3rd Quarter | 3rd Quarter | 3rd Quarter | 3rd Quarter | 3rd Quarter | 3rd Quarter | |||||||||||||||||
2021 |
2020 |
2021 |
2020 |
2021 |
2020 |
2021 |
2020 |
|||||||||||||||||
Net sales | $ |
109,904 |
|
$ |
104,174 |
$ |
42,234 |
$ |
35,973 |
$ |
30,472 |
$ |
29,764 |
$ |
37,198 |
$ |
38,437 |
|||||||
Gross profit | $ |
54,269 |
|
$ |
48,307 |
$ |
23,703 |
$ |
21,263 |
$ |
17,104 |
$ |
16,042 |
$ |
13,462 |
$ |
11,002 |
|||||||
Operating income | $ |
22,375 |
|
$ |
16,021 |
$ |
17,122 |
$ |
16,827 |
$ |
13,305 |
$ |
11,466 |
$ |
2,027 |
$ |
745 |
|||||||
Adjustments: | ||||||||||||||||||||||||
Transactional expenses |
|
(232 |
) |
|
570 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||
FDA PMTA |
|
960 |
|
|
5,271 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||
Adjusted operating income | $ |
23,103 |
|
$ |
21,862 |
$ |
17,122 |
$ |
16,827 |
$ |
13,305 |
$ |
11,466 |
$ |
2,027 |
$ |
745 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005310/en/
Media Contacts
212.896.1204
rcona@kcsa.com
Investor Contacts
502.774.9238
ir@tpbi.com
Source:
FAQ
What were the Q3 2021 financial results for TPB?
How much did TPB increase its share repurchase authorization?
What challenges did TPB face in Q3 2021?